Moreover, given the recalcitrance of advanced CRC in general, the therapeutic approach of DCLK1 kinase inhibition may have the potential to overcome the limitation of current therapies by suppressing the cancer stemness and inflammatory TME that fuel fatal recurrence and metastasis. Here, DCLK1 is linked to cancer.